Fulcrum Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Hi, everyone. Good afternoon, and welcome to the 41st Annual JPMorgan Healthcare Conference. My name is Lalita Sundarrajan, and I'm an associate here on the JPMorgan healthcare banking team. It's my absolute pleasure to introduce our speaker for today's presentation, CEO of Fulcrum Therapeutics, Robert Gould. He's joined on stage by CFO, Esther Rajavelu; and Chief Medical Officer, Santiago Arroyo. With that, Robert, I'll turn it over to you.
Well, thank you very much, and thank you to JPMorgan for the opportunity to present to you this afternoon. What we'll be looking at today is the progress we've made over the last year at Fulcrum Therapeutics and also looking forward to some of the highlights of what we anticipate coming in 2023. As such, I'll be presenting forward-looking statements.
Fulcrum was started about 7 years ago with the vision of treating genetically defined diseases with small molecules to change the lives of patients with genetically defined diseases
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
